Privacy Policy
Signals Blog

Contributors

Categories

CCRM’s inaugural investor symposium: Recap and key takeaways

Matthew Mistry is a Market and Equity Analyst at CCRM, where he conducts investment diligence, market analyses, participates in company creation activities and supports strategic business development. He joined CCRM from the Ontario Bioscience Innovation Organization...

Right Turn: Paying attention to blood cancers

September is National Blood Cancer Awareness Month. “Few people know that many of today’s fundamental treatments for various cancers, like chemotherapy, began with blood cancer research,” explains Alicia Talarico, President, Leukemia & Lymphoma...

Up in the air

Flying a small plane may be easy to learn. Flying a jumbo jet safely, with hundreds of people’s lives in your hands, takes decades of training and testing. Cell and gene therapy today is a bit like a rookie pilot: it will still be some time of carefully monitored...

The Betrayal: turning cancer against itself

I honestly believe that we’re living in the most exciting time for cancer therapeutics. The past few years (dare I say decades, even?) have pushed the boundaries of cancer treatment from radiation and chemotherapy to the use of cancer-targeted antibodies, oncolytic...